Impact Biomedical (IBO) Operating Income (2022 - 2026)
Impact Biomedical's (IBO) quarterly Operating Income came in at -$2.3 million in Q1 2026, down 126.63% YoY from $8.6 million in Q1 2025, and down 141.46% on a QoQ basis from -$948000.0 in Q3 2025.
Impact Biomedical (IBO) Operating Income (2022 - 2026) Analysis & Trends
Impact Biomedical (IBO) has 5 years of Operating Income data on file, last reported at -$2.3 million in Q1 2026.
- Quarterly Operating Income fell 126.63% year-over-year to -$2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.4 million (up 81.38% YoY) and the FY2024 annual result came in at -$28.8 million, down 613.83% from the prior year.
- Operating Income slipped to -$2.3 million in Q1 2026, from -$948000.0 in the prior quarter.
- In the past five years, Operating Income ranged from a high of -$626000.0 in Q2 2024 to a low of -$26.2 million in Q4 2024.
- A 5-year average of -$2.7 million and a median of -$1.0 million in 2025 frame the typical range for Operating Income.
- The widest YoY moves for Operating Income: up 37.9% in 2024, down 2202.99% in 2024.
- Tracing IBO's Operating Income over 5 years: stood at -$1.0 million in 2022, then retreated by 10.37% to -$1.1 million in 2023, then plunged by 2202.99% to -$26.2 million in 2024, then soared by 96.39% to -$948000.0 in 2025, then tumbled by 141.46% to -$2.3 million in 2026.
- The last three Operating Income figures came in at -$2.3 million (Q1 2026), -$948000.0 (Q3 2025), and -$1.2 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 133.12 Mn |
| 10 | Impact Biomedical | 49.54 Mn | 49.53 Mn | 2,000.00 | -702,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -702,000.00 |
| Mar 31, 2026 | -2.29 Mn |
| Sep 30, 2025 | -948,000.00 |
| Jun 30, 2025 | -1.15 Mn |
| Mar 31, 2025 | -1.01 Mn |
| Dec 31, 2024 | -26.23 Mn |
| Sep 30, 2024 | -1.13 Mn |
| Jun 30, 2024 | -626,000.00 |
| Mar 31, 2024 | -771,000.00 |
| Dec 31, 2023 | -1.14 Mn |
| Sep 30, 2023 | -1.08 Mn |
| Jun 30, 2023 | -1.01 Mn |
| Mar 31, 2023 | -803,000.00 |
| Dec 31, 2022 | -1.03 Mn |
| Sep 30, 2022 | -889,000.00 |
| Jun 30, 2022 | -750,000.00 |